Abstract
The homology of the inhibitor binding site regions on the surface of cyclin-dependent kinases (CDKs) makes actual CDK inhibitors unable to bind specifically to their molecular targets. Most of them are ATP competitive inhibitors with low specificity that also affect the phosphorylation mechanisms of other nontarget kinases giving rise to harmful side effects. So, the search of specific and potent inhibitors able to bind to the desired CDK target is still a pending issue. Structure based drug design minimized the erroneous binding and increased the affinity of the inhibitor interaction. In the case of CDKs their activation and regulation mechanisms mainly depend on protein-protein interactions (PPIs). The design of drugs targeting these PPIs makes feasible and promising towards the discovery of new and specific CDK inhibitors. Development of peptide inhibitors for a target protein is an emerging approach in computer aided drug designing. This chapter describes in detail methodology for use of the VitAL-Viterbi algorithm for de novo peptide design of CDK2 inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gadek JW, Maurer M, Zulehner N et al (2011) Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol 226:341–349
Senderowicz AM (2000) Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19:6600–6606
Andrews MJI, McInnes C, Kontopidis G et al (2004) Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin dependent kinase complexes. Org Biomol Chem 2:2735–2741
Mutoh M, Lung FDT, Long YQ et al (1999) p21Waf/cip1 carboxyl-terminal peptide exhibited cyclin-dependent kinase inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res 59:3480–3488
Unal EB, Gursoy A, Erman B (2010) VitAL: Viterbi algorithm for de novo peptide design. PLoS One 5(6), e10926
HyperChem (TM) Professional 7.51, Hypercube, Inc., 1115 NW 4th Street, Gainesville, Florida 32601, USA
Morris GM, Goodsell DS, Halliday RS et al (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19:1639–1662
Berman HM, Westbrook J, Feng Z et al (2000) The Protein Data Bank. Nucleic Acids Res 28(1):235–242
Liao C, Sitzmann M, Pugliese A et al (2011) Software and resources for computational medicinal chemistry. Future Med Chem 3(8):1057–1085
Lowe ED, Tews I, Cheng KY et al (2002) Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry 41:5625
Kuhlman B, Dantas G, Ireton GC et al (2003) Design of a novel globular protein fold with atomic-level accuracy. Science 302:1364–1368
Sievers SN, Karanicolas J, Chang HW et al (2011) Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 475:96–100
Tuncbag N, Kar G, Gursoy A et al (2009) Towards inferring time dimensionality in protein-protein interaction networks by integrating structures: the p53 example. Mol Biosyst 5:1770–1778
Keskin O, Yuret D, Gursoy A et al (2004) Relationships between amino acid sequence and backbone torsion angle preferences in proteins. Proteins 55:992–998
Acknowledgments
The authors thank the DST New Delhi (SR/FT/CS-66/2010) for financial support. AK and SKT gratefully acknowledge DST (New Delhi) for JRF and CSIR (New Delhi) for SRF respectively. One of the authors thanks CSIR-CDRI for support.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Arumugasamy, K., Tripathi, S.K., Singh, P., Singh, S.K. (2016). Protein-Protein Interaction for the De Novo Design of Cyclin-Dependent Kinase Peptide Inhibitors. In: Orzáez, M., Sancho Medina, M., Pérez-Payá, E. (eds) Cyclin-Dependent Kinase (CDK) Inhibitors. Methods in Molecular Biology, vol 1336. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2926-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2926-9_6
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2925-2
Online ISBN: 978-1-4939-2926-9
eBook Packages: Springer Protocols